<DOC>
	<DOCNO>NCT00398450</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , azacitidine , work different way stop growth tumor cell , either kill cell stop dividing . Interferon alfa may interfere growth tumor cell . Giving azacitidine together interferon alfa may effective treatment melanoma . PURPOSE : This phase I trial study side effect best dose azacitidine give together interferon alfa treat patient metastatic melanoma .</brief_summary>
	<brief_title>Azacitidine Interferon Alfa Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) azacitidine combination interferon alfa-2b patient metastatic melanoma . - Determine MTD regimen biologically active patient . - Define describe toxicity associate regimen . Secondary - Determine , preliminarily , response patient treat regimen . - Describe , preliminarily , time progression overall survival patient treat regimen . OUTLINE : This dose-escalation study azacitidine . Patients receive azacitidine subcutaneously ( SC ) daily day 1-5 ( week 1 ) follow interferon alfa-2b SC 3 day week week 2-4 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos azacitidine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 12 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic melanoma At least one lesion appropriate 3 separate punch core needle biopsy Must receive fail ≥ 1 prior systemic treatment metastatic disease PATIENT CHARACTERISTICS : ECOG performance status 02 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT &lt; 2 time ULN Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known allergy azacitidine , interferon alfa , benzyl alcohol , mannitol No uncontrolled infection No known HIV positivity No hepatitis B hepatitis C infection PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 3 week since prior systemic therapy More 4 week since prior radiotherapy target lesion evidence progression No concurrent radiotherapy target lesions No concurrent oral IV corticosteroid Topical cream ocular steroid drop allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>